HandiHaler: Clinical Trials

4 trials of HandiHaler, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 completed. 4 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 44Completed 4

Follow HandiHaler: new trials by email Literature Review of HandiHaler trials Research Report on HandiHaler

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC /VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
budesonide/formoterol, albuterol/salbutamol, FF/UMEC/VI - Pulmonary Disease, Chronic Obstructive
Phase 4CompletedGlaxoSmithKline7322018-06-252020-10-28
A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
budesonide/formoterol, albuterol/salbutamol, FF/UMEC/VI - Pulmonary Disease, Chronic Obstructive
Phase 4CompletedGlaxoSmithKline7292018-06-252020-10-28
A Comparative Study Between Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy Versus Tiotropium Monotherapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
FF/UMEC/VI, Tiotropium, Albuterol/salbutamol - Pulmonary Disease, Chronic Obstructive
Phase 4CompletedGlaxoSmithKline8002018-03-292021-07-15
Study of Inhaler Device Attributes Investigating Critical and Overall Errors, Ease of Use, and Preference Between a Number of Inhaler Devices
ELLIPTA, DISKUS/ACCUHALER, MDI - Pulmonary Disease, Chronic Obstructive
Phase 4CompletedGlaxoSmithKline5692014-08-282017-05-23

Conditions studied

Pulmonary Disease, Chronic Obstructive (4)

Sponsors

GlaxoSmithKline (4)

Countries

United States (3)  ·  Czechia (2)  ·  Germany (2)  ·  Netherlands (2)  ·  Poland (1)  ·  Russia (1)  ·  United Kingdom (1)

Results publications

PMID 27883002

NIH funding

2017 (3)